Neurophyxia B.V.   Report issue

For profit Phase 2
Founded: Hertogenbosch Netherlands (2008)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2012
NCT01626924
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

hexahydro-2-imino-1h-thieno(3,4-d)imidazole-4-pentanoic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asphyxia (Phase 2)

Asphyxia Neonatorum (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1